Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital
October 07 2020 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late
clinical-stage biopharmaceutical company working to develop the
first FDA-approved ophthalmic formulation of bevacizumab-vikg for
use in retinal indications, today announced that Lawrence Kenyon,
President, CEO and CFO of Outlook Therapeutics, will participate at
the BIO Investor Forum Digital taking place on October 13-15, 2020.
The Outlook Therapeutics corporate presentation
will be available on-demand during the conference to those
registered to attend. Additionally, management will also be
available to participate in virtual one-on-one meetings with
qualified members of the investor community who are registered to
attend. Interested parties can request a meeting through the
conference portal. For additional information about the conference,
please visit the conference website.
About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a late clinical-stage
biopharmaceutical company working to develop ONS-5010 / LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab-vikg for use in retinal indications, including wet
AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics
expects to commercialize it as the first and only FDA-approved
ophthalmic formulation of bevacizumab-vikg for use in treating
retinal diseases in the United States, United Kingdom, Europe,
Japan and other markets. Outlook Therapeutics expects to file
ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a)
regulatory pathway. For more information, please visit
www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Jessica MorrisAccount ExecutiveLaVoie Health
ScienceT: 857.701.9731jmorris@lavoiehealthscience.com
Investor Inquiries:Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Apr 2023 to Apr 2024